Publications
73
Citations
755
Est. group size
~14
Recurring co-author estimate
Active years
30
Publishing since 1997
Diana Thomas's work centers on pediatric brain tumors, especially gliomas such as diffuse intrinsic pontine glioma (DIPG) and high-grade glioma, combining molecular/genetic characterization of tumors with clinical trials testing new drug and radiation treatments. Much of this research is done through large multi-institution collaborations and childhood cancer data-sharing initiatives aimed at improving diagnosis and treatment for children and young adults.
Publication output has grown markedly over the last decade, rising from about 1 paper per year in 2017-2019 to a peak of 15 in 2023, with continued high activity (average of 8.4 papers/year over the last five years).
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- 1464 Pediatric Posterior Fossa Diffuse Low-grade Astrocytomas with KIAA1549::BRAF Fusion Correspond to Pilocytic Astrocytoma by Epigenetic Signature and Clinical Outcome
Laboratory Investigation · 2026
- Childhood cancer data initiative: expanded access to tumor molecular profiling for children, adolescents, and young adults
JNCI Journal of the National Cancer Institute · 2025
- Molecular, histologic, and clinical characterization of methylation class pleomorphic xanthoastrocytoma: An analysis of 469 tumors
Neuro-Oncology Advances · 2025
- Pediatric Brain Tumors
Elsevier eBooks · 2025
- CCDI-COG molecular characterization initiative: The expanding data on childhood cancer.
Journal of Clinical Oncology · 2025
- TIP-30. Molecularly-guided phase 2 umbrella trial for children and young adults with newly-diagnosed high-grade glioma (HGG) including diffuse intrinsic pontine glioma (DIPG): CONNECT TarGeT (Targeted pediatric HGG therapy) trial in progress
Neuro-Oncology · 2025
- Phase 2 trial of veliparib, local irradiation, and temozolomide in patients with newly diagnosed high-grade glioma: a Children’s Oncology Group study
Neuro-Oncology · 2024
- Molecular characterization of gliomas and glioneuronal tumors amid Noonan syndrome: cancer predisposition examined
Frontiers in Oncology · 2024
- DIPG-56. BRAINSTEM TUMOR BIOPSY: A SINGLE INSTITUTE EXPERIENCE OF SAFETY AND FEASIBILITY IN A LOW-MIDDLE INCOME COUNTRY (LMIC)
Neuro-Oncology · 2024
- PATH-13. MOLECULAR AND BIOLOGY CORRELATIVE RESULTS FROM THE PHASE 1B TRIAL OF UNESBULIN (PTC596) WITH RADIOTHERAPY IN CHILDREN NEWLY-DIAGNOSED WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)
Neuro-Oncology · 2024
- 2021 updates to the World Health Organization classification of adult-type and pediatric-type diffuse gliomas: a clinical practice review
Chinese Clinical Oncology · 2023
- METB-04. THE MOLECULAR CHARACTERIZATION INITIATIVE (MCI): A CLINICAL AND GENOMIC RESOURCE FOR THE PEDIATRIC BRAIN TUMOR COMMUNITY
Neuro-Oncology · 2023
- DIPG-54. UPDATED FINDINGS FROM THE PHASE IB STUDY OF UNESBULIN (PTC596) IN CHILDREN WITH NEWLY-DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)
Neuro-Oncology · 2023
- LGG-14. TREATMENT OF TWO PEDIATRIC FGFR-ALTERED LOW-GRADE GLIONEURONAL TUMORS WITH MEK INHIBITION
Neuro-Oncology · 2023
- Supplementary Data from Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma
2023
- Neuro-Oncology×23
- Frontiers in Oncology×2
- Acta Neuropathologica Communications×2
- medRxiv×2
- bioRxiv (Cold Spring Harbor Laboratory)×2
- Kathleen M. Schieffer
Medicine · The Ohio State University
- Bradley Elder
Medicine · The Ohio State University
- Fernando M. Núñez
Medicine · The Ohio State University
- Daniel R. Boué
Medicine · The Ohio State University
- Jonathan L. Finlay
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile